Katrine Fladeland Iversen

7PUBLICATIONS
17CO-AUTHORS
Innate immunityMedical infection agents (incl. prions)Gene and molecular therapyMedical molecular engineering of nucleic acids and proteinsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 10, 2026
Natural killer cells from patients relapsing on daratumumab therapy express an exhausted-associated phenotype.

|Feb 09, 2026
Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma.

Kieran Brennan, Katrine F Iversen, Alfonso Blanco-Fernández

|Oct 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.

Stefan Knop, Monika Szarejko, Norbert Grząśko

|Aug 26, 2024
Mechanisms of resistance to daratumumab in patients with multiple myeloma.

Katrine Fladeland Iversen

|Nov 11, 2022
Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59.

Kieran Brennan, Katrine F Iversen, Alfonso Blanco-Fernández

|Sep 21, 2022
High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.

Katrine Fladeland Iversen, Line Nederby, Thomas Lund

Pageof 2

Frequent Collaborators

2 joint publications

Torben Plesner

2 joint publications

Margaret M Mc Gee

1 joint publications

Stefan Knop

1 joint publications

Norbert Grząśko